The study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of Trichomylin® in healthy adult participants.~Up to 56 participants will be enrolled into 1 of 4 SAD cohorts (8 per cohort) and 3 MAD cohorts (8 per cohort). Participants will undergo a Screening period between 21 days and 28 days prior to randomization/dose administration (for SAD and MAD respectively), admission to the clinical research unit (CRU), pre-dose assessment, post-dose assessment, and a final end of study (EOS)/follow-up or early termination (ET) visit (if applicable).
This is a first in human, randomized, double blind, SAD (with food effect) followed by a MAD study of Trichomylin® conducted in healthy adult participants.